President Dr Mohamed Muizzu has ratified an amendment to the Drugs Act (Act No. 17/2011), enabling the use of methylphenidate as a first-line treatment for Attention Deficit Hyperactivity Disorder (ADHD) in the Maldives.

The amendment was enacted through Presidential Decree No. 10/2026, issued under Section 3-4(e) of the Drugs Act, and was published in the Government Gazette, coming into immediate effect.

The decision follows a recommendation by the National Drug Control Council, which was subsequently reviewed and approved by the Cabinet.

In accordance with Section 3-4(c) of the Act, the proposal was then submitted to the People’s Majlis for consideration.

During the 17th sitting of the first session of Parliament held on 11 May 2026, members voted in favor of removing methylphenidate from Item No. 89 of the list of prohibited substances under Schedule I of the Act.

With the amendment now in force, the legal framework permits the regulated availability of methylphenidate, allowing it to be prescribed as a primary treatment option for individuals diagnosed with ADHD.

The reform is expected to enhance access to evidence-based care for ADHD, aligning national policy more closely with internationally accepted clinical practices.